Sociedad Americana de Hirudoterapia

Heparin-Induced Thrombocytopenia and Portal Vein Thrombosis in Patients With Hepatocellular Carcinoma After Hepatectomy: A Case Report

Research article published in Cureus (2025)

Última actualización: June 18, 2026Revisado por: ASH Editorial Board
Research article — evidence reviewArticle reference
Evidence: Case reportEnsayos clínicosSakio et al. · Cureus, 2025

Abstract

Portal vein thrombosis and heparin-induced thrombocytopenia (HIT) caused by postoperative heparin administration is a potentially fatal disease. There have been a few cases of portal vein thrombosis and HIT developing after hepatectomy. We report a rare case of HIT and portal vein thrombosis after hepatectomy. A 79-year-old woman with liver cirrhosis and hypertension was referred to our hospital for the evaluation of the elevated tumor marker and liver tumor diagnosed by ultrasonography. In laboratory findings, alpha-fetoprotein and protein induced by vitamin K absence were elevated. Contrast-enhanced computed tomography (CT) scan findings showed that 28 mm and 17 mm diameter, round-shaped tumors enhanced heterogeneously with infiltration in the left hepatic vein and pulmonary embolization. Hepatocellular carcinoma and pulmonary embolism were diagnosed. She underwent lateral segmentectomy along with venous tumor embolus resection. Pathological findings showed that the tumor was moderate to well-differentiated adenocarcinoma invading the capsule with liver cirrhosis. Tumor embolization was suspected preoperatively to be an organizing thrombus. After surgery, she was treated with heparin for the prevention of deep venous thrombosis. At postoperative day 15, the sudden onset of the decline of platelets, the activity of antithrombin III, and the elevation of D-dimer were found. On physical examination, there were no symptoms. The 4T's score was 7. CT scan showed a portal vein thrombosis. The antibody for HIT was elevated. HIT was diagnosed. We stopped the heparin and started the argatroban administration. The platelet level increased to the normal range, and the D-dimer level decreased. After the reduction of portal vein and pulmonary thrombosis, she was discharged from the hospital on postoperative day 28.

Abstract sourced from PubMed (NCBI) for the cited record. See the original publication for the authoritative version.

Publication typeCase ReportsJournal Article

Resumen

Peer-reviewed clinical and outcomes research relevant to medicinal leech therapy and its biology. Indexed in PubMed and verified against the NCBI record.

Por qué esto importa para la hirudoterapia

Este informe de caso describe a una mujer de 79 años que desarrolló trombocitopenia inducida por heparina (HIT) y trombosis de la vena porta después de una hepatectomía para carcinoma hepatocelular; se administró heparina posoperatoria para la profilaxis de la TVP, una puntuación 4T's de 7 y un anticuerpo HIT positivo confirmaron el diagnóstico, y la suspensión de la heparina y el inicio de argatroban llevaron a la recuperación plaquetaria y a la reducción del trombo. Es relevante para la hirudoterapia como un recordatorio de que la anticoagulación basada en heparina alrededor de procedimientos microquirúrgicos y reconstructivos conlleva su propio riesgo trombótico mediado por inmunidad, lo que justifica por qué se discuten clínicamente adjuntos no farmacológicos como la terapia con sanguijuelas para la congestión venosa local, y por qué la elección del anticoagulante importa en pacientes afectados por HIT. Aviso honesto: este es un informe de caso único sin implicación en terapia con sanguijuelas; ilustra una complicación de la heparina y su manejo, no ningún beneficio de la hirudoterapia.

Citación

Heparin-Induced Thrombocytopenia and Portal Vein Thrombosis in Patients With Hepatocellular Carcinoma After Hepatectomy: A Case Report.

Sakio et al. · Cureus, 2025

Contexto clínico relacionado

Añadido a la biblioteca ASH: May 28, 2026 · Última actualización del sitio: June 18, 2026

Este sitio web proporciona información educativa y no constituye consejo médico, diagnóstico ni recomendaciones de tratamiento. La terapia con sanguijuelas medicinales conlleva riesgos clínicamente significativos y debe ser realizada únicamente por profesionales calificados bajo protocolos aprobados institucionalmente. La autorización 510(k) de la FDA para sanguijuelas medicinales se limita a indicaciones específicas; las discusiones sobre uso investigativo y fuera de indicación se señalan correspondientemente. Para orientación médica específica, consulte a un profesional de salud calificado.